Abstract The pharmacy profession has undergone substantial change over the last two to three decades. Whilst medicine supply still remains a central function, pharma-
Introduction
Healthcare systems across the world, and in particular Western healthcare systems, have undergone major reforms in response to political and economic pressures [1] [2] [3] [4] [5] [6] . This has resulted in attempts to maximise existing resources, both financial and staffing, to improve delivery of effective and efficient healthcare [7, 8] . Healthcare policies of many countries now encourage the public to take control of their own health. Community pharmacists have been identified as a very accessible professional group that can optimise patient use of medicines and facilitate patient self-care [9] [10] [11] . This will require community pharmacists to combine their traditional role of medicine supply (and medicines expertise) [12, 13] with the need to provide additional patient-focused services [14] [15] [16] . This re-alignment of the job role has started to see an expansion in their scope of practice, involving public health services [17] [18] [19] , inclusion into national systems to report adverse drug reactions [20] and granting of prescribing rights [21] [22] [23] .
The self-care concept has been supported by governments making more medicines freely available. Most medicines that have been 'switched' from prescription control are to relieve signs and symptoms associated with acute episodes of illness, but recently medicines for the management of long-term conditions (e.g. statins and tamsulosin) have also been made available.. Australia, Germany, UK and the USA are seen as world leaders in medicine switching [24] . For example, over 90 prescription medicines have been made non-prescription in the UK between 1983 and 2013; in the USA, from 1976 to 2003, there were 71 prescription to over-the-counter switches [25] . Community pharmacists therefore find themselves the custodians of an increasing arsenal of medicines that can be used to manage a wider range of signs and symptoms. This affords pharmacists opportunities to monitor for adverse events associated with these products as well as identifying drug-induced signs and symptoms.
Diagnostic Ability of Community Pharmacists
The role of 'responding to symptoms' has been associated with community pharmacy practice for decades, but with increased medicine deregulation (including European-wide deregulation, for example orlistat [26] ) and role expansion, pharmacists need to be well schooled in how to diagnose. However, limited research has assessed community pharmacists' ability to be good diagnosticians. Pharmacy researchers have primarily assessed what questions pharmacists ask and the actions they take when dealing with standardised patient scenarios [27, 28] , or what influences pharmacist selection of non-prescription medicines [29] . Only recently has exploratory research begun to investigate the process by which they make a diagnosis [30, 31] . Data suggest that community pharmacists rely heavily on protocol-driven questioning that may lead to mis-diagnosis. Indeed, consumer organisations have criticised the diagnostic ability of pharmacists when assessed using mystery shoppers [32] [33] [34] [35] . In the pharmacy's defence, the underpinning knowledge and skills required to diagnose from a patient's presenting signs and symptoms are relatively recent introductions to pharmacy undergraduate curricula [36] , and even when elements of diagnosis are covered, for example, physical examination (which is a pre-requisite for course accreditation in the USA), it is not necessarily in the context of making a diagnosis [37] . In many European curricula, it still does not feature [38] . Given the development of contemporary pharmacy practice and current research findings there seems to be a need to equip current and future pharmacists with better diagnostic skills. In the UK, this 'skills shortage' of practitioners has been partially recognised with the launch of a national learning and development framework on consultation skills in April 2014 [39] .
Community Pharmacists' Contribution to Pharmacovigilance
Many of the roles and responsibilities being afforded to community pharmacists require greater use of clinical skills, especially those involving consultation, diagnosis and therapeutic intervention [40] . What is unknown is will these facilitated self-care models affect how community pharmacists contribute to medicine safety? Looking at current practice, it appears that reporting by community pharmacists is low, especially when it is voluntary. Two examples are used here for illustration. Adverse drug reaction reporting by pharmacists is now well established in many countries [20] , and where data are available, community pharmacists tend to be worse at reporting than their hospital colleagues [41] [42] [43] . Barriers to poor reporting are well documented [44, 45] , but lack of financial incentives has been additionally cited by community pharmacists [46] . A further example is drawn from the UK National Reporting and Learning System (NRLS), which captures patient safety incidents for England and Wales. A 2006 study found pharmacy staff were unlikely to report adverse events, regardless of severity. A lack of understanding about reporting and mistrust about its purpose were given as reasons for non-reporting [47] . This situation appears not to have markedly improved, in that NRLS statistics for 2011-2012 showed community pharmacists reported 1,343 incidents compared with 3,967 by primary care doctors [48] . Incidents reported by community pharmacists were almost entirely based (96 % of reports) on medicine safety issues (compared with 18 % for doctors), which does highlight the highly focused nature of pharmacy reporting. When incentivised, it appears community pharmacists are more likely to document and report medicine safety issues. Two new medicine adherence services (New Medicines Services in the UK and Home Medicines Review in Australia) allow pharmacists to assess patient understanding and the use of new and established medicines [49, 50] . Both services require each patient consultation to be documented and form the basis for remuneration and require pharmacists to report on medication safety issues. In the first 9 months after the New Medicines Service was launched, adverse drug reaction reporting increased by 120 % [51] .
Improving Pharmacovigilance from Community Pharmacies
Current medication/patient safety incident reporting rates are low. There is a need within community pharmacies to improve reporting, and of course learning, from such incidents. The key question is how community pharmacists' can be encouraged to report more given that role expansion will provide increased diagnostic opportunity. We believe that changes need to be made both within the pharmacy profession and to existing healthcare structures.
The Profession
Pharmacy has been, and in some countries still is, a predominantly science-based course, yet if pharmacy education is to keep pace with current and future changes in practice then curricula have to adapt to become more patient focused. This will not necessarily be about providing knowledge, for example, pharmacovigilance is reasonably well understood and covered at undergraduate level [52] [53] [54] . Teaching focus needs to be patient centred and will require students to develop attributes that reinforce the need to put patient welfare first. Pharmacy could learn from other professions, such as medicine in this regard [55] . From such foundations, concepts of clinical reasoning, patient safety and clinical accountability can be instilled. Concepts can then be translated into practice by actions that include diagnosis, shared decision making, documentation and reporting. To ensure this behaviour becomes routine, pharmacy students should have greater exposure to first-hand clinical practice. The extent to which this is happening internationally varies enormously; but in general the experiential opportunities afforded to pharmacy students is much less than other healthcare students. This exposure to practice and working with others in multidisciplinary environments will foster and consolidate a more patient-focused approach to care, something that is not always apparent in pharmacy curricula. Inevitably, educational changes take time to percolate into clinical practice, creating a need for postgraduate opportunities to bridge this gap. One such example is a course to become an independent prescriber where clinical accountability and diagnostic ability have greater prominence [56] . Research undertaken with prescribing pharmacists has largely focused on their attitudes toward this new role but one study found that prescribing pharmacists were more likely to report suspected adverse drug reactions than nurse prescribers [57] . Whether training to be a prescriber affects attitude toward pharmacovigilance is unknown; more studies are required to establish if independent prescribers routinely incorporate patient safety reporting into their practice. If this is the case, then there is a compelling argument to instruct undergraduates in a similar fashion.
Finally, it must be acknowledged that potential barriers to practice change are pharmacists themselves. Work has highlighted time, money and lack of interest as constraints, yet when models have been trialled to remove such obstacles sustained practice change has not resulted [58, 59] . Evidence also suggests that pharmacists are reluctant to move away from a supply function and shy away from taking responsibility for the patient [60] [61] [62] .
Organisational Change
The environment in which community pharmacists work hampers their ability to better contribute to medication and patient safety. New ways of working need to be incorporated into clinical practice. Changes in the way services are delivered and integrated in existing healthcare structures need consideration. Having access to shared care records would be one way in which primary healthcare services could be more closely aligned. Access to records would enable, and may encourage, community pharmacists to document, report and reflect on their activities when facilitating patient self-care. This could be further strengthened by introducing formal referral mechanisms to medical practitioners following pharmacist diagnosis to allow follow-up and determine outcomes. This may necessitate patient registration with a named community pharmacy. Registration at a community pharmacy is not unknown as exemplified by the Scottish minor ailments service [63] . Such changes need to be incentivised. Evidence suggests that incentives do influence community pharmacists' activity. When providing contracted services (through government or medical insurance) the remuneration models need to move away from prescription supply to activity that has reward for providing more patient-focused activities. Such models are being introduced, although the inclusion of pharmacovigilance-type activities is low [50, 64, 65] . For private transactions (e.g. over-the-counter consultations), changes to legislation may hold the key to increased documentation and incident reporting even though there is evidence that educational intervention around adverse drug reactions has a positive effect on reporting rates [66] . In all likelihood, a combination of incentive and legal compulsion will be required. Regardless of approach taken, the success and speed of adoption will depend on strong leadership, appropriate resources and creation of sustainable infrastructures.
Conclusion
Community pharmacy is in transition from a medicine supply service to providing cognitive services, as self-care policies in Western societies become more prominent.
The workforce is currently poorly prepared to take on some of these roles that involve the ability to diagnose and accept clinical accountability. To ensure patient safety, the profession needs to develop a patient-centred, medicine-focused culture that embraces reporting medicine safety issues. This must be supported by healthcare policy that allows better integration of community pharmacy services.
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